Toxicological properties of Δ⁹-tetrahydrocannabinol and cannabidiol

1Murphy SM1, Puwanant A, Griggs RC; Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol 2012;72:481–90. doi: 10.1002/ana.23672 Murphy SM1 Puwanant A Griggs RC Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network. Unintended effects of orphan product designation for rare neurological diseases Ann Neurol 201272481 90 10.1002/ana.23672Open DOISearch in Google Scholar

2ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 2017;103:1–36. doi: 10.1007/978-3-319-45541-9_1 ElSohly MA Radwan MM Gul W Chandra S Galal A Phytochemistry of Cannabis sativa L Prog Chem Org Nat Prod 20171031 36 10.1007/978-3-319-45541-9_1Open DOISearch in Google Scholar

3Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, editors. Cannabinoids. Handbook of experimental pharmacology. Vol 168. Berlin, Heidelberg: Springer; 2005. p. 1–51. Pertwee RG Pharmacological actions of cannabinoids In Pertwee RG editors Cannabinoids. Handbook of experimental pharmacology. Vol 168 Berlin, Heidelberg Springer 2005 p 1–5110.1007/3-540-26573-2_1Search in Google Scholar

4Pertwee RG. The diverse CB₁ and CB₂ receptor pharmacology of three plant cannabinoids: Δ⁹-tetrahydrocannabinol, cannabidiol and Δ⁹-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199–215. doi: 10.1038/sj.bjp.0707617 Pertwee RG The diverse CB₁ and CB₂ receptor pharmacology of three plant cannabinoids: Δ⁹-tetrahydrocannabinol, cannabidiol and Δ⁹-tetrahydrocannabivarin Br J Pharmacol 2008153199 215 10.1038/sj.bjp.0707617Open DOISearch in Google Scholar

5McPartland JM, Duncan M, Di Marzo V, Pertwee R. Are cannabidiol and Δ⁹-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2015;172:737–53. doi: 10.1111/ bph.12944 McPartland JM Duncan M Di Marzo V Pertwee R Are cannabidiol and Δ⁹-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review Br J Pharmacol 2015172737 53 10.1111/bph.12944Open DOISearch in Google Scholar

6Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ⁹-tetrahydrocannabinol. Neuropsychopharmacology 2018;43:142–54. doi: 10.1038/npp.2017.209 Boggs DL Nguyen JD Morgenson D Taffe MA Ranganathan M Clinical and preclinical evidence for functional interactions of c a n n a bi d i o l a n d Δ ⁹-tetrahydrocannabinol Neuropsychopharmacology 201843142 54 10.1038/npp.2017.209Open DOISearch in Google Scholar

7Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med 2018;49:2–6. doi: 10.1016/j.ejim.2018.01.001 Abuhasira R Shbiro L Landschaft Y Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America Eur J Intern Med 2018492 6 10.1016/j.ejim.2018.01.001Open DOISearch in Google Scholar

8Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003;7:469–75. doi: 10.1016/S1367-5931(03)00079-6 Cravatt BF Lichtman AH Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Curr Opin Chem Biol 20037469 75 10.1016/S1367-5931(03)00079-6Open DOISearch in Google Scholar

9Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Annex 1, Analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products. [displayed 05 March 2020]. Available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Annex 1, Analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products. [displayed 05 March 2020] Available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdfSearch in Google Scholar

10Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397–411. doi: 10.1111/j.1476-5381.2008.00048.x Pertwee RG Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br J Pharmacol 2009156397 411 10.1111/j.1476-5381.2008.00048.x269768119226257Open DOISearch in Google Scholar

11Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol 2013;168:554–75. doi: 10.1111/j.1476-5381.2012.02223.x Kenakin T New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2 Br J Pharmacol 2013168554 75 10.1111/j.1476-5381.2012.02223.x357927922994528Open DOISearch in Google Scholar

12Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol 2013;18:872–81. doi: 10.1111/j.1369-1600.2011.00427.x Bedi G Cooper ZD Haney M Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers Addict Biol 201318872 81 10.1111/j.1369-1600.2011.00427.xOpen DOISearch in Google Scholar

13Abbott laboratorie, Limited. ^NMarinol® Product Monograph [displayed 14 April 2019]. Available at https://pdf.hres.ca/dpd_pm/00013378.PDF Abbott laboratorie, Limited. ^NMarinol® Product Monograph [displayed 14 April 2019 Available at https://pdf.hres.ca/dpd_pm/00013378.PDFSearch in Google Scholar

14Valeant Canada Limited. ^NCesamet® Product Monograph [displayed 28 April 2019]. Available at https://pdf.hres.ca/dpd_pm/00007760.PDF Valeant Canada Limited. ^NCesamet® Product Monograph [displayed 28 April 2019 Available at https://pdf.hres.ca/dpd_pm/00007760.PDFSearch in Google Scholar

15Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;21:1–25. doi: 10.1016/j.jep.2006.02.001 Ben Amar M Cannabinoids in medicine: A review of their therapeutic potential J Ethnopharmacol 2006211 25 10.1016/j.jep.2006.02.001Open DOISearch in Google Scholar

16McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10(Suppl):15A-22A. doi: 10.1155/2005/242516 McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 200510Suppl15A 22A 10.1155/2005/242516Open DOISearch in Google Scholar

17Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999;141:385–94. doi: 10.1007/s002130050848 Haney M Ward AS Comer SD Foltin RW Fischman MW Abstinence symptoms following oral THC administration to humans Psychopharmacology (Berl) 1999141385 94 10.1007/s002130050848Open DOISearch in Google Scholar

18Lile JA, Kelly TH, Hays LR. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol. Clin Neuropharmacol 2010;33:235–42. doi: 10.1097/WNF.0b013e3181e77428 Lile JA Kelly TH Hays LR Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol Clin Neuropharmacol 201033235 42 10.1097/WNF.0b013e3181e77428Open DOISearch in Google Scholar

19Lemberger L, Rubin A, Wolen R, DeSante K, Rowe H, Forney R, Pence P. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 1982;9(Suppl B): 17– 23. doi: 10.1016/s0305-7372(82)80031-5 Lemberger L Rubin A Wolen R DeSante K Rowe H Forney R Pence P Pharmacokinetics, metabolism and drug-abuse potential of nabilone Cancer Treat Rev 19829Suppl B 17–23 10.1016/s0305-7372(82)80031-5Open DOISearch in Google Scholar

20Sullivan HR, Hanasono GK, Miller WM, Wood PG. Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes. Xenobiotica 1987;17:459–68. doi: 10.3109/00498258709043952 Sullivan HR Hanasono GK Miller WM Wood PG Species specificity in the metabolism of nabilone Relationship between toxicity and metabolic routes. Xenobiotica 198717459 68 10.3109/00498258709043952Open DOISearch in Google Scholar

21Hanasono GK, Sullivan HR, Gries CL, Jordan WH, Emmerson JL. A species comparison of the toxicity of nabilone, a new synthetic cannabinoid. Fundam Appl Toxicol 1987;9:185–97. doi: 10.1016/0272-0590(87)90042-x Hanasono GK Sullivan HR Gries CL Jordan WH Emmerson JL A species comparison of the toxicity of nabilone, a new synthetic cannabinoid Fundam Appl Toxicol 19879185 97 10.1016/0272-0590(87)90042-xOpen DOISearch in Google Scholar

22Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 1973;25:363–72. doi: 10.1016/0041-008x(73)90310-4 Thompson GR Rosenkrantz H Schaeppi UH Braude MC Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys Toxicol Appl Pharmacol 197325363 72 10.1016/0041-008x(73)90310-4Open DOISearch in Google Scholar

23Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of Δ⁹-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996;30:109–17. doi: 10.1006/faat.1996.0048 Chan PC Sills RC Braun AG Haseman JK Bucher JR Toxicity and carcinogenicity of Δ⁹-tetrahydrocannabinol in Fischer rats and B6C3F1 mice Fundam Appl Toxicol 199630109 17 10.1006/faat.1996.00488812248Open DOISearch in Google Scholar

24Luthra UL, Rosenkrantz H, Heyman IA, Braude MC. Differential neurochemistry and temporal pattern in rats treated orally with Δ⁹-tetrahydrocannabinol for periods up to six months. Toxicol Appl Pharmacol 1975;32:418–31. doi: 10.1016/0041-008X(75)90232-X Luthra UL Rosenkrantz H Heyman IA Braude MC Differential neurochemistry and temporal pattern in rats treated orally with Δ⁹-tetrahydrocannabinol for periods up to six months Toxicol Appl Pharmacol 197532418 31 10.1016/0041-008X(75)90232-XOpen DOISearch in Google Scholar

25International Agency for Research on Cancer (IARC). Report of the Advisory Group to Recommend Priorities for IARC Monographs during 2015–2019. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon: IARC; 2014. International Agency for Research on Cancer (IARC). Report of the Advisory Group to Recommend Priorities for IARC Monographs during 2015–2019. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans Lyon IARC 2014Search in Google Scholar

26Fleischman RW, Hayden DW, Naqvi RH, Rosenkrantz H, Braude MC. The embryotoxic effects of cannabinoids in rats and mice. J Environ Pathol Toxicol 1980;4:471–82. PMID: 6255054 Fleischman RW Hayden DW Naqvi RH Rosenkrantz H Braude MC The embryotoxic effects of cannabinoids in rats and mice J Environ Pathol Toxicol 19804471 82 PMID: 6255054Search in Google Scholar

27Haley SL, Wright PL, Plank JB, Keplinger ML, Braude MC, Calendra JC. The effect of natural and synthetic Δ⁹-tetrahydrocannabinol on fetal development. Toxicol Appl Pharmacol 1973;25:450. Haley SL Wright PL Plank JB Keplinger ML Braude MC Calendra JC The effect of natural and synthetic Δ⁹-tetrahydrocannabinol on fetal development Toxicol Appl Pharmacol 197325450Search in Google Scholar

28Keplinger ML, Wright RL, Haley SL, Plank JB, Braude MC, Calandra JC. The effect of natural and synthetic Δ⁹-tetrahydrocannabinol on reproductive and lactation performance in albino rats. Toxicol Appl Pharmacol 1973;25:449. Keplinger ML Wright RL Haley SL Plank JB Braude MC Calandra JC The effect of natural and synthetic Δ⁹-tetrahydrocannabinol on reproductive and lactation performance in albino rats Toxicol Appl Pharmacol 197325449Search in Google Scholar

29Brigss GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Philadelphia (PA): Lippincott Williams and Wilkins; 2011. Brigss GG Freeman RK Yaffe SJ Drugs in Pregnancy and Lactation Philadelphia (PA) Lippincott Williams and Wilkins; 2011Search in Google Scholar

30Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patinets with AIDS. J Pain Symptom Manage 1995;10:89–97. doi: 10.1016/0885-3924(94)00117-4 Beal JE Olson R Laubenstein L Morales JO Bellman P Yangco B Lefkowitz L Plasse TF Shepard KV Dronabinol as a treatment for anorexia associated with weight loss in patinets with AIDS J Pain Symptom Manage 19951089 97 10.1016/0885-3924(94)00117-4Open DOISearch in Google Scholar

31Sallan SE, Zinberg NE, Frei E 3^rd Antiemetic effect of Δ⁹-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795–7. doi: 10.1056/ NEJM197510162931603 Sallan SE Zinberg NE Frei E 3^rd Antiemetic effect of Δ⁹-tetrahydrocannabinol in patients receiving cancer chemotherapy N Engl J Med 1975293795 7 10.1056/NEJM197510162931603Open DOISearch in Google Scholar

32Frytak S, Moertel CG, O’Fallon JR, Rubin J, Creagan ET, O’Connell MJ, Schutt AJ, Schwartau NW. Δ⁹-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979;91:825–30. doi: 10.7326/0003-4819-91-6-825 Frytak S Moertel CG O’Fallon JR Rubin J Creagan ET O’Connell MJ Schutt AJ Schwartau NW Δ⁹-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy A comparison with prochlorperazine and a placebo Ann Intern Med 197991825 30 10.7326/0003-4819-91-6-825Open DOISearch in Google Scholar

33Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA. Δ⁹-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 1979;21:338–40. PMID: 516362 Kluin-Neleman JC Neleman FA Meuwissen OJ Maes RA Δ⁹-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo Vet Hum Toxicol 197921338 40 PMID: 516362Search in Google Scholar

34Lucas VS Jr, Laszlo J. Δ⁹-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 1980;243:1241–3. doi: 10.1001/jama.1980.03300380021014 Lucas VS Jr Laszlo J Δ⁹-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy JAMA 19802431241 3 10.1001/jama.1980.03300380021014Open DOISearch in Google Scholar

35Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 1980;140:1431–3. doi: 10.1001/ archinte.140.11.1431 Orr LE McKernan JF Bloome B Antiemetic effect of tetrahydrocannabinol Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis Arch Intern Med 19801401431 3 10.1001/archinte.140.11.1431Open DOISearch in Google Scholar

36Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of Δ⁹-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135–8. doi: 10.1056/ NEJM198001173020302 Sallan SE Cronin C Zelen M Zinberg NE Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of Δ⁹-tetrahydrocannabinol and prochlorperazine N Engl J Med 1980302135 8 10.1056/NEJM198001173020302Open DOISearch in Google Scholar

37Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981;21 (Suppl 1 ) : 38 S– 42 S . doi : 10.1002/j.1552-4604.1981.tb02571.x Neidhart JA Gagen MM Wilson HE Young DC Comparative trial of the antiemetic effects of THC and haloperidol J Clin Pharmacol 198121 (Sup p l 1 ) : 3 8 S– 4 2 S 10.1002/j.1552-4604.1981.tb02571.xOpen DOISearch in Google Scholar

38Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr, Harwood S, Franklin R, Cohen MH. Antiemetic efficacy of levonantradol compared to Δ⁹-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985;69:109–12. PMID: 2981616 Citron ML Herman TS Vreeland F Krasnow SH Fossieck BE Jr Harwood S Franklin R Cohen MH Antiemetic efficacy of levonantradol compared to Δ⁹-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting Cancer Treat Rep 198569109 12 PMID 2981616Search in Google Scholar

39Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Salva K, Wiernik PH, Holroyde CP, Hammill S, Shepard K, Plasse T. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991;6:352–9. doi: 10.1016/0885-3924(91)90026-Z Lane M Vogel CL Ferguson J Krasnow S Saiers JL Hamm J Salva K Wiernik PH Holroyde CP Hammill S Shepard K Plasse T Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting J Pain Symptom Manage 19916352 9 10.1016/0885-3924(91)90026-ZOpen DOISearch in Google Scholar

40May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res 2016;8:49–55. doi: 10.2147/CMAR.S81425 May MB Glode AE Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics Cancer Manag Res 2016849 55 10.2147/CMAR.S81425486961227274310Open DOISearch in Google Scholar

41Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 1982;9(Suppl 2):25–33. doi: 10.1016/s0305-7372(82)80032-7 Johansson R Kilkku P Groenroos M A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 19829Suppl 225 33 10.1016/s0305-7372(82)80032-7Open DOISearch in Google Scholar

42Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 1982;9(Suppl 2):39–44. doi: 10.1016/s0305-7372(82)80034-0 Wada JK Bogdon DL Gunnell JC Hum GJ Gota CH Rieth TE Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy Cancer Treat Rev 19829Suppl 239 44 10.1016/s0305-7372(82)80034-0Open DOISearch in Google Scholar

43Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983;48:657–63. doi: 10.1038/bjc.1983.247 Ahmedzai S Carlyle DL Calder IT Moran F Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy Br J Cancer 198348657 63 10.1038/bjc.1983.24720115106315040Open DOISearch in Google Scholar

44Panagis G, Mackey B, Vlachou S. Cannabinoid regulation of brain reward processing with an emphasis on the role of CB₁ receptors: A step back into the future. Front Psychiatry 2014;5:1–20. doi: 10.3389/fpsyt.2014.00092 Panagis G Mackey B Vlachou S Cannabinoid regulation of brain reward processing with an emphasis on the role of CB₁ receptors: A step back into the future Front Psychiatry 201451 20 10.3389/fpsyt.2014.00092411718025132823Open DOISearch in Google Scholar

45European Medicines Agency (EMA). Guideline on the non-clinical investigation of the dependence potential of medicinal products [displayed 2 March 2020]. Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdf European Medicines Agency (EMA). Guideline on the nonclinical investigation of the dependence potential of medicinal products [displayed 2 March 2020 Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdfSearch in Google Scholar

46Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, Costello MR, Farahi J, Saxena S, Monterosso J, London ED. Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 2009;34:282–9. doi: 10.1038/ npp.2008.87 Brody AL Mandelkern MA Olmstead RE Allen-Martinez Z Scheibal D Abrams AL Costello MR Farahi J Saxena S Monterosso J London ED Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette Neuropsychopharmacology 200934282 9 10.1038/npp.2008.87277799018563061Open DOISearch in Google Scholar

47Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, Sakr E, Castillo F, Moadel T, O’Malley SS, Krystal JH, Abi-Dargham A. Sex differences in striatal dopamine release in young adults after oral alcohol challenge: apositron emission tomography imaging study with [¹¹C]raclopride. Biol Psychiatry 2010;68:689 – 96.doi:10.1016/j.biopsych.2010.06.005 Urban NB Kegeles LS Slifstein M Xu X Martinez D Sakr E Castillo F Moadel T O’Malley SS Krystal JH Abi-Dargham A Sex differences in striatal dopamine release in young adults after oral alcohol challenge: apositron emission tomography imaging study with [¹¹C]raclopride Biol Psychiatry 2010;68:689–96 10.1016/j.biopsych.2010.06.005294953320678752Open DOISearch in Google Scholar

48Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of Δ⁹-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology (Berl) 2015;232:2723–9. doi: 10.1007/s00213-015-3915-0 Bossong MG Mehta MA van Berckel BN Howes OD Kahn RS Stokes PR Further human evidence for striatal dopamine release induced by administration of Δ⁹-tetrahydrocannabinol (THC): selectivity to limbic striatum Psychopharmacology (Berl) 20152322723 9 10.1007/s00213-015-3915-0481619625801289Open DOISearch in Google Scholar

49Harris RT, Waters W, McLendon D. Evaluation of reinforcing capability of Δ⁹-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 1974;37:23–9. doi: 10.1007/bf00426679 Harris RT Waters W McLendon D Evaluation of reinforcing capability of Δ⁹-tetrahydrocannabinol in rhesus monkeys Psychopharmacologia 19743723 9 10.1007/bf00426679Open DOISearch in Google Scholar

50Mansbach RS, Nicholson KL, Martin BR, Balster RL. Failure of! Δ⁹-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol 1994;5:219–25. doi: 10.1097/00008877-199404000-00014 Mansbach RS Nicholson KL Martin BR Balster RL Failure of! Δ⁹-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys Behav Pharmacol 19945219 25 10.1097/00008877-199404000-0001411224271Open DOISearch in Google Scholar

51Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000;3:1073–4. doi: 10.1038/80577 Tanda G Munzar P Goldberg SR Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 200031073 4 10.1038/8057711036260Open DOISearch in Google Scholar

52Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of Δ⁹-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 2003;169:135–40. doi: 10.1007/s00213-003-1484-0 Justinova Z Tanda G Redhi GH Goldberg SR Self-administration of Δ⁹-tetrahydrocannabinol (THC) by drug naive squirrel monkeys Psychopharmacology (Berl) 2003169135 40 10.1007/s00213-003-1484-0Open DOISearch in Google Scholar

53Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by Δ⁹-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995;56:2073–80. doi: 10.1016/0024-3205(95)00191-8 Lepore M Vorel SR Lowinson J Gardner EL Conditioned place preference induced by Δ⁹-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward Life Sci 1995562073 80 10.1016/0024-3205(95)00191-8Open DOISearch in Google Scholar

54Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295–7. doi: 10.1056/NEJM197906073002302 Herman TS Einhorn LH Jones SE Nagy C Chester AB Dean JC Furnas B Williams SD Leigh SA Dorr RT Moon TE Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy N Engl J Med 19793001295 7 10.1056/NEJM197906073002302Open DOISearch in Google Scholar

55Food and Drug Organization (FDA). Center for drug evalution and research. Epidiolex. Summary review [displayed 28 April 2019]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000SumR.pdf Food and Drug Organization (FDA). Center for drug evalution and research. Epidiolex. Summary review [displayed 28 April 2019 Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000SumR.pdfSearch in Google Scholar

56European Medicines Agency (EMA). European Public Assessment report. Epidyolex, [displayed 05 March 2020]. Available at https://www.ema.europa.eu/en/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdf European Medicines Agency (EMA). European Public Assessment report. Epidyolex [displayed 05 March 2020 Available at https://www.ema.europa.eu/en/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdfSearch in Google Scholar

57Robert EM, Taylor NL, Martin BR, Wiley JL. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ⁹-tetrahydrocannabinol. Drug Alcohol Depend 2008;94:191–8. doi: 10.1016/j.drugalcdep.2007.11.017 Robert EM Taylor NL Martin BR Wiley JL Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ⁹-tetrahydrocannabinol Drug Alcohol Depend 200894191 8 10.1016/j.drugalcdep.2007.11.017Open DOISearch in Google Scholar

58Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav 2018;88:162–171. doi: 10.1016/j.yebeh.2018.07.027 Schoedel KA Szeto I Setnik B Sellers EM Levy-Cooperman N Mills C Etges T Sommerville K Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial Epilepsy Behav 201888162 171 10.1016/j.yebeh.2018.07.027Open DOISearch in Google Scholar

59World Health Organization Expert Committee on Drug Dependence. Cannabidiol (CBD) Pre-Review Report Agenda Item 5.2 and Peer Review, 2017. Available AT https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf World Health Organization Expert Committee on Drug Dependence. Cannabidiol (CBD) Pre-Review Report Agenda Item 5.2 and Peer Review 2017 Available AT https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdfSearch in Google Scholar

60Lim SY, Sharan S, Woo S. Model-based analysis of cannabidiol dose-exposure relationship and bioavailability. Pharmacotherapy 2020. doi: 10.1002/phar.2377 Lim SY Sharan S Woo S Model-based analysis of cannabidiol dose-exposure relationship and bioavailability Pharmacotherapy 2020 10.1002/phar.2377Open DOISearch in Google Scholar

61Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, Hennig IM, Barrett DA, Constantinescu CS, Fischer PM, Gershkovich P. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res 2016;8:3448–59. PMCID: PMC5009397 Zgair A Wong JC Lee JB Mistry J Sivak O Wasan KM Hennig IM Barrett DA Constantinescu CS Fischer PM Gershkovich P Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines Am J Transl Res 201683448 59 PMCID: PMC5009397Search in Google Scholar

62Cherniakov I, Izgelov D, Domb AJ, Hoffman A. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci 2017;109:21–30. doi: 10.1016/j. ejps.2017.07.003 Cherniakov I Izgelov D Domb AJ Hoffman A The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model Eur J Pharm Sci 201710921 30 10.1016/j.ejps.2017.07.003Open DOISearch in Google Scholar

63Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69:1135–47. doi: 10.1007/s00228-012-1441-0 Stott CG White L Wright S Wilbraham D Guy GW A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray Eur J Clin Pharmacol 2013691135 47 10.1007/s00228-012-1441-0Open DOISearch in Google Scholar

64Ujváry I, Hanuš L. Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 2016;1:90–101. doi: 10.1089/can.2015.0012 Ujváry I Hanuš L Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy Cannabis Cannabinoid Res 2016190 101 10.1089/can.2015.0012Open DOISearch in Google Scholar

65Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 1991;40:523–32. doi: 10.1016/0091-3057(91)90358-9 Harvey DJ Samara E Mechoulam R Comparative metabolism of cannabidiol in dog, rat and man Pharmacol Biochem Behav 199140523 32 10.1016/0091-3057(91)90358-9Open DOISearch in Google Scholar

66Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 2010;31:367–95. doi: 10.1002/ bdd.720 Regan SL Maggs JL Hammond TG Lambert C Williams DP Park BK Acyl glucuronides: the good, the bad and the ugly Biopharm Drug Dispos 201031367 95 10.1002/bdd.720Open DOISearch in Google Scholar

67Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;58:118–31. doi: 10.1016/0041-008x(81)90122-8 Rosenkrantz H Fleischman RW Grant RJ Toxicity of short-term administration of cannabinoids to rhesus monkeys Toxicol Appl Pharmacol 198158118 31 10.1016/0041-008x(81)90122-8Open DOISearch in Google Scholar

68Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S. Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011– 20. doi: 10.1056/NEJMoa1611618 Devinsky O Cross JH Laux L Marsh E Miller I Nabbout R Scheffer IE Thiele EA Wright S Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome N Engl J Med 20173762011–20 10.1056/NEJMoa1611618Open DOISearch in Google Scholar

69Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:1888–97. doi: 10.1056/NEJMoa1714631 Devinsky O Patel AD Cross JH Villanueva V Wirrell EC Privitera M Greenwood SM Roberts C Checketts D VanLandingham KE Zuberi SM Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome N Engl J Med 20183781888 97 10.1056/NEJMoa1714631Open DOISearch in Google Scholar

70Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:1085–96. doi: 10.1016/S0140-6736(18)30136-3 Thiele EA Marsh ED French JA Mazurkiewicz-Beldzinska M Benbadis SR Joshi C Lyons PD Taylor A Roberts C Sommerville K Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 20183911085 96 10.1016/S0140-6736(18)30136-3Open DOISearch in Google Scholar

71Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A; CBD EAP study group. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res 2019;154:13–20. doi: 10.1016/j.eplepsyres.2019.03.015 Laux LC Bebin EM Checketts D Chez M Flamini R Marsh ED Miller I Nichol K Park Y Segal E Seltzer L Szaflarski JP Thiele EA Weinstock A; CBD EAP study group Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results Epilepsy Res 201915413 20 10.1016/j.eplepsyres.2019.03.015Open DOISearch in Google Scholar

72ClinicalTrials.gov database. GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes [displayed 4 March 2020]. Available at https://clinicaltrials.gov/ct2/show/record/NCT02224573 ClinicalTrials.gov database. GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes [displayed 4 March 2020 Available at https://clinicaltrials.gov/ct2/show/record/NCT02224573Search in Google Scholar

73Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234–46. doi: 10.1016/j. mehy.2005.08.026 Russo E Guy GW A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med Hypotheses 200666234 46 10.1016/j.mehy.2005.08.026Open DOISearch in Google Scholar

74Howlett AC, Scott DK, Wilken GH. Regulation of adenylate cyclase by cannabinoid drugs. Insights based n thermodynamic studies. Biochem Pharmacol 1989;38:3297–304. doi: 10.1016/0006-2952(89)90628-x Howlett AC Scott DK Wilken GH Regulation of adenylate cyclase by cannabinoid drugs Insights based n thermodynamic studies Biochem Pharmacol 1989383297 304 10.1016/0006-2952(89)90628-xOpen DOISearch in Google Scholar

75Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004;143:247– 50. doi: 10.1038/sj.bjp.0705920 Costa B Giagnoni G Franke C Trovato AE Colleoni M Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation Br J Pharmacol 2004143247–50 10.1038/sj.bjp.0705920157533315313881Open DOISearch in Google Scholar

76Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 2008;22:1017–24. doi: 10.1002/ptr.2401 Comelli F Giagnoni G Bettoni I Colleoni M Costa B Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved Phytother Res 2008221017 24 10.1002/ptr.240118618522Open DOISearch in Google Scholar

77Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 1995;23:825– 31. PMID: 7493549 Bornheim LM Kim KY Li J Perotti BY Benet LZ Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain Drug Metab Dispos 199523825–31 PMID 7493549Search in Google Scholar

78Wright MJ Jr, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ⁹-tetrahydrocannabinol. Br J Pharmacol 2013;170:1365–73. doi: 10.1111/bph.12199 Wright MJ Jr Vandewater SA Taffe MA Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ⁹-tetrahydrocannabinol Br J Pharmacol 20131701365 73 10.1111/bph.12199383868323550724Open DOISearch in Google Scholar

79Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ⁹-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 2005;27:799–810. doi: 10.1097/01. ftd.0000177223.19294.5c Nadulski T Pragst F Weinberg G Roser P Schnelle M Fronk EM Stadelmann AM Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ⁹-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract Ther Drug Monit 200527799 810 10.1097/01.ftd.0000177223.19294.5c16306858Open DOISearch in Google Scholar

80Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Δ⁹-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57:66–75. doi: 10.1373/clinchem.2010.152439 Karschner EL Darwin WD Goodwin RS Wright S Huestis MA Plasma cannabinoid pharmacokinetics following controlled oral Δ⁹-tetrahydrocannabinol and oromucosal cannabis extract administration Clin Chem 20115766 75 10.1373/clinchem.2010.152439371733821078841Open DOISearch in Google Scholar

81Medicines and Healthcare Products Regulatory Agency (MHRA). Public Assessment Report. Sativex oromucosal Spray [displayed 28 April 2019]. Available at http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf Medicines and Healthcare Products Regulatory Agency (MHRA). Public Assessment Report Sativex oromucosal Spray [displayed 28 April 2019 Available at http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdfSearch in Google Scholar

82Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J Neurosci Res 2011;89:1509–18. doi: 10.1002/jnr.22682 Sagredo O Pazos MR Satta V Ramos JA Pertwee RG Fernández-Ruiz J Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease J Neurosci Res 2011891509 18 10.1002/jnr.2268221674569Open DOISearch in Google Scholar

83Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417–24. doi: 10.1191/1352458504ms1048oa Vaney C Heinzel-Gutenbrunner M Jobin P Tschopp F Gattlen B Hagen U Schnelle M Reif M Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study Mult Scler 200410417 24 10.1191/1352458504ms1048oa15327040Open DOISearch in Google Scholar

84Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434–41. doi: 10.1191/1352458504ms1082oa Wade DT Makela P Robson P House H Bateman C Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult Scler 200410434 41 10.1191/1352458504ms1082oa15327042Open DOISearch in Google Scholar

85Wade DT, Makela PM, House H, Bateman C, Robson P. Longterm use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639–45. doi: 10.1177/1352458505070618 Wade DT Makela PM House H Bateman C Robson P Longterm use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis Mult Scler 200612639 45 10.1177/135245850507061817086911Open DOISearch in Google Scholar

86Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14(3):290–6. doi: 10.1111/j.1468-1331.2006.01639.x Collin C Davies P Mutiboko IK Ratcliffe S Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis Eur J Neurol 2007143290 6 10.1111/j.1468-1331.2006.01639.x17355549Open DOISearch in Google Scholar

87Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:285–95. doi: 10.1007/s00415-012-6634-z Serpell MG Notcutt W Collin C Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis J Neurol 2013260285 95 10.1007/s00415-012-6634-z22878432Open DOISearch in Google Scholar

88Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O’Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451–9. doi: 10.1179/016164109X12590518685660 Collin C Ehler E Waberzinek G Alsindi Z Davies P Powell K Notcutt W O’Leary C Ratcliffe S Nováková I Zapletalova O Piková J Ambler Z A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis Neurol Res 201032451 9 10.1179/016164109X1259051868566020307378Open DOISearch in Google Scholar

89Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122–31. doi: 10.1111/j.1468-1331.2010.03328.x Novotna A Mares J Ratcliffe S Novakova I Vachova M Zapletalova O Gasperini C Pozzilli C Cefaro L Comi G Rossi P Ambler Z Stelmasiak Z Erdmann A Montalban X Klimek A Davies P; Sativex Spasticity Study Group A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis Eur J Neurol 2011181122 31 10.1111/j.1468-1331.2010.03328.x21362108Open DOISearch in Google Scholar

90Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regime, in the relief of central europathic pain in patients with multiple sclerosis. J Neurol 2013;260:984–77. doi: 10.1007/s00415-012-6739-4 Langford RM Mares J Novotna A Vachova M Novakova I Notcutt W Ratcliffe S A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regime, in the relief of central europathic pain in patients with multiple sclerosis J Neurol 2013260984 77 10.1007/s00415-012-6739-423180178Open DOISearch in Google Scholar

91García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013;13(3 Suppl 1):9–13. doi: 10.1586/ern.13.4 García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain Expert Rev Neurother 2013133 Suppl 19 13 10.1586/ern.13.423369054Open DOISearch in Google Scholar

92Rekand T. THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 2014;71(Suppl 1):4–9. doi: 10.1159/000357742 Rekand T THC:CBD spray and MS spasticity symptoms: data from latest studies Eur Neurol 201471Suppl 14 9 10.1159/00035774224457846Open DOISearch in Google Scholar

93Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharm 2009;32:41–7. doi: 10.1097/WNF.0B013 E3181633497 Aragona M Onesti E Tomassini V Conte A Gupta S Gilio F Pantano P Pozzilli C Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study Clin Neuropharm 20093241 7 10.1097/WNF.0B013E318163349718978501Open DOISearch in Google Scholar

94Robson P. Abuse potential and psychoactive effects of Δ⁹-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10:675–85. doi: 10.1517/14740338.2011.575778 Robson P Abuse potential and psychoactive effects of Δ⁹-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine Expert Opin Drug Saf 201110675 85 10.1517/14740338.2011.57577821542664Open DOISearch in Google Scholar